Rho-kinase mediates TNF-α-induced MCP-1 expression via p38 MAPK signaling pathway in mesangial cells

Biochemical and Biophysical Research Communications

Volumn 402, Issue 4, 2010, Pages 725-730

  Matoba, Keiichiro ^a   Kawanami, Daiji ^a   Ishizawa, Sho ^a   Kanazawa, Yasushi ^a   Yokota, Tamotsu ^a   Utsunomiya, Kazunori ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

MCP 1; Mesangial cell; P38 MAPK; Rho kinase; TNF

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; MONOCYTE CHEMOTACTIC PROTEIN 1; RHO FACTOR; RHO KINASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; MESANGIUM CELL; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SECRETION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

AMIDES; ANIMALS; CELL LINE; CHEMOKINE CCL2; CHEMOTAXIS; ENZYME INHIBITORS; GLOMERULONEPHRITIS; MESANGIAL CELLS; MICE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PYRIDINES; RHO-ASSOCIATED KINASES; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78649449324     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.10.093     Document Type: Article

References (27)

1. Nathan C.F. Secretory products of macrophages. J. Clin. Invest. 1987, 79:319-326.
2. Ortiz A., Bustos C., Alonso J., Alcázar R., López-Armada M.J., Plaza J.J., González E., Egido J. Involvement of tumor necrosis factor-alpha in the pathogenesis of experimental and human glomerulonephritis. Adv. Nephrol. Necker Hosp. 1995, 24:53-77.
3. Pai R., Ha H., Kirschenbaum M.A., Kamanna V.S. Role of tumor necrosis factor-alpha on mesangial cell MCP-1 expression and monocyte migration: mechanisms mediated by signal transduction. J. Am. Soc. Nephrol. 1996, 7:914-923.
4. Lan H.Y. Therapeutic effects of cytokine blockade in glomerulonephritis. Nephrol. Dial. Transplant. 1998, 13:7-9.
5. Takemura T., Yoshioka K., Murakami K., Akano N., Okada M., Aya N., Maki S. Cellular localization of inflammatory cytokines in human glomerulonephritis. Virchows Arch. 1994, 424:459-464.
6. Navarro J.F., Mora C., Maca M., Garca J. Inflammatory parameters are independently associated with urinary albumin in type 2 diabetes mellitus. Am. J. Kidney Dis. 2003, 42:53-61.
7. Etienne-Manneville S., Hall A. Rho GTPases in cell biology. Nature 2002, 420:629-635.
8. Kamiyama M., Utsunomiya K., Taniguchi K., Yokota T., Kurata H., Tajima N., Kondo K. Contribution of Rho A and Rho kinase to platelet-derived growth factor-BB-induced proliferation of vascular smooth muscle cells. J. Atheroscler. Thromb. 2003, 10:117-123.
9. Shimokawa H., Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler. Thromb. Vasc. Biol. 2005, 25:1767-1775.
10. Nishikimi T., Koshikawa S., Ishikawa Y., Akimoto K., Inaba C., Ishimura K., Ono H., Matsuoka H. Inhibition of Rho-kinase attenuates nephrosclerosis and improves survival in salt-loaded spontaneously hypertensive stroke-prone rats. J. Hypertens. 2007, 25:1053-1063.
11. Peng F., Wu D., Gao B., Ingram A.J., Zhang B., Chorneyko K., McKenzie R., Krepinsky J.C. RhoA/Rho-kinase contribute to the pathogenesis of diabetic renal disease. Diabetes 2008, 57:1683-1692.
12. Gojo A., Utsunomiya K., Taniguchi K., Yokota T., Ishizawa S., Kanazawa Y., Kurata H., Tajima N. The Rho-kinase inhibitor, fasudil, attenuates diabetic nephropathy in streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 2007, 568:242-247.
13. Satoh S., Yamaguchi T., Hitomi A., Sato N., Shiraiwa K., Ikegaki I., Asano T., Shimokawa H. Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction. Eur. J. Pharmacol. 2002, 455:169-174.
14. Hunter I., Nixon G.F. Spatial compartmentalization of tumor necrosis factor (TNF) receptor 1-dependent signaling pathways in human airway smooth muscle cells. Lipid rafts are essential for TNF-alpha-mediated activation of RhoA but dispensable for the activation of the NF-kappaB and MAPK pathways. J. Biol. Chem. 2006, 281:34705-34715.
15. Kawanami D., Mahabeleshwar G.H., Lin Z., Atkins G.B., Hamik A., Haldar S.M., Maemura K., Lamanna J.C., Jain M.K. Kruppel-like factor 2 inhibits hypoxia-inducible factor 1alpha expression and function in the endothelium. J. Biol. Chem. 2009, 284:20522-20530.
16. Sarafi M.N., Garcia-Zepeda E.A., MacLean J.A., Charo I.F., Luster A.D. Murine monocyte chemoattractant protein (MCP)-5: a novel CC chemokine that is a structural and functional homologue of human MCP-1. J. Exp. Med. 1997, 185:99-109.
17. Neumark E., Anavi R., Witz I.P., Ben-Baruch A. MCP-1 expression as a potential contributor to the high malignancy phenotype of murine mammary adenocarcinoma cells. Immunol. Lett. 1999, 68:141-146.
18. Liu Z.H., Chen S.F., Zhou H., Chen H.P., Li L.S. Glomerular expression of C-C chemokines in different types of human crescentic glomerulonephritis. Nephrol. Dial. Transplant. 2003, 18:1526-1534.
19. Mai M., Geiger H., Hilgers K.F., Veelken R., Mann J.F., Dämmrich J., Luft F.C. Early interstitial changes in hypertension-induced renal injury. Hypertension 1993, 22:754-765.
20. Chow F., Ozols E., Nikolic-Paterson D.J., Atkins R.C., Tesch G.H. Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury 2004, 65:116-128.
21. Galkina E., Ley K. Leukocyte recruitment and vascular injury in diabetic nephropathy. J. Am. Soc. Nephrol. 2006, 17:368-377.
22. Ordóñez-Morán P., Larriba M.J., Pálmer H.G., Valero R.A., Barbáchano A., Duñach M., de Herreros A.G., Villalobos C., Berciano M.T., Lafarga M., Muñoz A. RhoA-ROCK and p38MAPK-MSK1 mediate vitamin D effects on gene expression, phenotype, and Wnt pathway in colon cancer cells. J. Cell Biol. 2008, 183:697-710.
23. Rupérez M., Rodrigues-Díez R., Blanco-Colio L.M., Sánchez-López E., Rodríguez-Vita J., Esteban V., Carvajal G., Plaza J.J., Egido J., Ruiz-Ortega M. HMG-CoA reductase inhibitors decrease angiotensin II-induced vascular fibrosis: role of RhoA/ROCK and MAPK pathways. Hypertension 2007, 50:377-383.
24. Yune T.Y., Lee J.Y., Jung G.Y., Kim S.J., Jiang M.H., Kim Y.C., Oh Y.J., Markelonis G.J., Oh T.H. Minocycline alleviates death of oligodendrocytes by inhibiting pro-nerve growth factor production in microglia after spinal cord injury. J. Neurosci. 2007, 27:7751-7761.
25. Robert P., Tsui P., Laville M.P., Livi G.P., Sarau H.M., Bril A., Berrebi-Bertrand I. EDG1 receptor stimulation leads to cardiac hypertrophy in rat neonatal myocytes. J. Mol. Cell. Cardiol. 2001, 33:1589-1606.
26. Geoffroy K., Troncy L., Wiernsperger N., Lagarde M., El Bawab S. Glomerular proliferation during early stages of diabetic nephropathy is associated with local increase of sphingosine-1-phosphate levels. FEBS Lett. 2005, 579:1249-1254.
27. Versteilen A.M., Korstjens I.J., Musters R.J., Groeneveld A.B., Sipkema P. Rho kinase regulates renal blood flow by modulating eNOS activity in ischemia-reperfusion of the rat kidney. Am. J. Physiol. Renal Physiol. 2006, 291:F606-F611.